POLBF Stock Price, Chart, Stats & News

Poolbeg Pharma plc operates as a clinical-stage pharmaceutical company, headquartered in London, United Kingdom, with a focus on developing treatments for infectious diseases. Its current product pipeline includes: POLB 001: A p38 MAP Kinase inhibitor being advanced for the treatment of severe influenza. POLB 002: An innovative, first-in-class RNA-based immunotherapy, acquired through a licensing agreement, designed for intranasal administration to combat various respiratory viral infections.